Role of adiponectin in insulin-resistant hypertension and atherosclerosis

Hypertension Research

Volumn 26, Issue 9, 2003, Pages 705-710

  Murakami, Hideyuki ^a   Ura, Nobuyuki ^a   Furuhashi, Masato ^a   Higashiura, Katsuhiro ^a   Miura, Tetsuji ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Atherosclerosis; Hypertension; Insulin resistance; Pulse wave velocity

Indexed keywords

ADIPONECTIN; GLUCOSE; IMMUNOREACTIVE INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEALTH SURVEY; HOMEOSTASIS; HORMONE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; JAPAN; MALE; MULTIPLE REGRESSION; POPULATION RESEARCH; PULSE WAVE; RISK FACTOR; RURAL POPULATION; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; AGE FACTORS; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTEINS; RISK FACTORS;

EID: 0141927466     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.705     Document Type: Article

References (50)

1. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
3. Despres JP, Lamarche B, Mauriege P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
4. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83: 2773-2776.
5. Haffner SM: Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999; 84: 11J-14J.
6. Takezako T, Saku K, Zhang B, et al: Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Circ J 1999; 63: 666-673.
7. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
8. Tsuchihashi K, Hikita N, Hase M, et al: Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi-quantitative coronary angiography. Intern Med 1999; 38: 691-697.
9. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
10. Shimamoto K, Hirata A, Fukuoka M, et al: Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23: I29-I33.
11. Osei K: Insulin resistance and systemic hypertension. Am J Cardiol 1999; 84: 33J-36J.
12. Iimura O: Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19: S1-S8.
13. Hyakukoku M, Higashiura K, Ura N, et al: Tissue specificity and selective resistance of insulin signaling in vasculature and skeletal muscle. Hypertens Res 2003; 26: 169-176.
14. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
15. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
16. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
17. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
18. Togashi N, Ura N, Higashiura K, et al: The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
19. Agata J, Miyazaki Y, Takada M, et al: Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. Hypertens Res 1998; 21: 57-62.
20. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
21. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
22. Weyer C, Funahashi T, Tanaka S, et al: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
23. Okamoto Y, Arita Y, Nishida M, et al: An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50.
24. Kubota N, Terauchi Y, Yamauchi T, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.
25. Scherer PE, Williams S, Fogliano M, et al: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
26. Nakano Y, Tobe T, Choi-Miura NH, et al: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996; 120: 803-812.
27. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
28. Maeda K, Okubo K, Shimomura I, et al: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
29. Shapiro L, Colman DR: Structural biology of cadherins in the nervous system. Curr Opin Neurobiol 1998; 8: 593-599.
30. Hotta K, Funahashi T, Bodkin NL, et al: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.
31. Combs TP, Berg AH, Obici S, et al: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-1881.
32. Berg AH, Combs TP, Du X, et al: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
33. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
34. Lindsay RS, Funahashi T, Hanson RL, et al: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
35. Goldstein BJ: Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 3G-10G.
36. Yang WS, Lee WJ, Funahashi T, et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
37. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
38. Furuhashi M, Ura N, Murakami H, et al: Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 2002; 174: 321-329.
39. Matsuda M, Shimomura I, Sata M, et al: Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.
40. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
41. Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
42. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
43. Ouchi N, Kihara S, Arita Y, et al: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
44. Kappes A, Loffler G: Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32: 548-554.
45. Fasshauer M, Klein J, Neumann S, et al: Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 142-146.
46. Maeda N, Takahashi M, Funahashi T, et al: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
47. Halleux CM, Takahashi M, Delporte ML, et al: Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107.
48. Fasshauer M, Klein J, Neumann S, et al: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089.
49. Nishizawa H, Shimomura I, Kishida K, et al: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741.
50. Yamauchi T, Kamon J, Waki H, et al: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-41254.